129
Views
5
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

, , , ORCID Icon, & ORCID Icon
Pages 129-140 | Published online: 12 Jan 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lauren Mason, Saad Jafri, Isabelle Dortonne & John D Sheppard$suffix/text()$suffix/text(). (2021) Emerging therapies for dry eye disease. Expert Opinion on Emerging Drugs 26:4, pages 401-413.
Read now

Articles from other publishers (4)

John D. Sheppard & Kelly K. Nichols. (2023) Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape. Ophthalmology and Therapy 12:3, pages 1397-1418.
Crossref
Elisabeth M Messmer, Sajjad Ahmad, José M Benitez del Castillo, Ewa Mrukwa-Kominek, Maurizio Rolando, Oksana Vitovska & Christophe Baudouin. (2022) Management of inflammation in dry eye disease: Recommendations from a European panel of experts. European Journal of Ophthalmology 33:3, pages 1294-1307.
Crossref
Bridgitte Shen Lee, Melissa Toyos, Paul Karpecki, Jessica Schiffbauer & John Sheppard. (2022) Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials. Ophthalmology and Therapy 11:4, pages 1333-1369.
Crossref
. 2022. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics 67 89 .